Capital Research Global Investors
PCVX icon

Capital Research Global Investors’s Vaxcyte PCVX Stock Holding History

Capital Research Global Investors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.6M Sell
836,761
-75,927
-8% -$4.12M 0.01% 347
2026
Q1 		$53M Buy
912,688
+69,710
+8% +$3.78M 0.01% 353
2025
Q4 		$38.9M Hold
842,978
– – 0.01% 364
2025
Q3 		$30.4M Sell
842,978
-3,928,808
-82% -$130M 0.01% 383
2025
Q2 		$155M Sell
4,771,786
-1,338,322
-22% -$43.9M 0.03% 250
2025
Q1 		$231M Sell
6,110,108
-100,415
-2% -$8.03M 0.05% 206
2024
Q4 		$508M Buy
6,210,523
+1,312,302
+27% +$130M 0.1% 142
2024
Q3 		$560M Buy
4,898,221
+764,677
+18% +$68.9M 0.12% 134
2024
Q2 		$312M Sell
4,133,544
-6,977
-0.2% -$475K 0.07% 174
2024
Q1 		$283M Buy
4,140,521
+700,414
+20% +$48.5M 0.06% 200
2023
Q4 		$216M Buy
3,440,107
+75,980
+2% +$3.95M 0.05% 222
2023
Q3 		$172M Hold
3,364,127
– – 0.05% 243
2023
Q2 		$168M Buy
3,364,127
+511,121
+18% +$24.2M 0.05% 249
2023
Q1 		$107M Buy
2,853,006
+47,004
+2% +$1.99M 0.03% 271
2022
Q4 		$135M Buy
2,806,002
+2,291,146
+445% +$89.9M 0.04% 251
2022
Q3 		$12.7M Buy
+514,856
New +$13.1M ﹤0.01% 380

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Capital Research Global Investors's PCVX Position: Q2 2026 in Review

Capital Research Global Investors reduced its Vaxcyte (PCVX) stake by 8.3% in Q2 2026, selling an estimated $4.12M and leaving 836,761 shares worth $48.6M. The position accounts for 0.01% of the portfolio, ranked #347.

Capital Research Global Investors first reported a position in PCVX in Q3 2022 and has held it in 16 quarters since. The position peaked at $560M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Capital Research Global Investors held 836,761 shares of Vaxcyte worth $48.6M as of Q2 2026.
  • Capital Research Global Investors sold 75,927 Vaxcyte shares in Q2 2026, an estimated $4.12M.
  • Vaxcyte made up 0.01% of Capital Research Global Investors's portfolio in Q2 2026, its #347 holding.
  • Capital Research Global Investors first reported a position in Vaxcyte in Q3 2022 and has held it in 16 quarters since.
  • Capital Research Global Investors's Vaxcyte position peaked at $560M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.